Skip to main content

Table 1 Characteristics of Selected Studies

From: Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis

First Author /Principal Investigator

Year

Study Name/Identifier

Study Type

Disease Type

Age: Mean (SD)

Male Gender:

N (%)

Benson [6]

2018

NEURO-TTR: NCT01737398

RCT

ATTRv-PN

60 (14)

41 (68%)

Berk [7]

2013

NA

RCT

ATTRv-PN

59 (12)

44 (67%)

Coelho [8]

2012

FX005: NCT00409175

RCT

ATTRv-PN

38 (13)

26 (43%)

Hernandez-Ojeda [28]

2012

NA

RCT

DPN

57 (9)

6 (24%)

Hor [29]

2018

NCT01973400

RCT

DPN

57 (9)

63 (42%)

Karama

2020

NA

Non-interventional study

CMT

51 (13)

6 (50%)

DPN

65 (11)

4 (36%)

ATTRv-PN

67 (7)

9 (90%)

IPN

66 (13)

7 (58%)

Luigetti [30]

2018

NA

Non-interventional study

ATTRv-PN

69 (9)

15 (83%)

Mundayat [31]

2018

THAOS

Non-interventional study

ATTRv-PN

41 (9)

NA

Sahenk [19]

2005

NA

RCT

CMT

33 (5)

3 (75%)

Shy [32]

2008

NA

Non-interventional study

CMT

40 (19)

30 (42%)

Tesfaye [33]

2007

Rochester Diabetic Neuropathy Study: NCT00044408 and NCT00044395

RCT

DPN

48 (9)

115 (44%)

Windebank [34]

2004

NA

RCT

Small fiber peripheral neuropathy

62 (11)

NA

Ziegler [35]

1999

ALADIN 3

RCT

DPN

57 (6)

83 (50%)

Ziegler [37]

2009

AV-007-IM: NCT00483730

RCT

DPN

56 (6)

77 (27%)

Ziegler [36]

2011

NATHAN 1: NCT00977483

RCT

DPN

54 (8)

150 (67%)

  1. Abbreviations: CMT Charcot-Marie-Tooth disease, DPN diabetic peripheral neuropathy, ATTRv-PN hereditary transthyretin amyloidosis with polyneuropathy, NA not applicable, RCT randomized controlled trial, SD standard deviation
  2. aUnpublished dataset